SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-18-007194
Filing Date
2018-03-30
Accepted
2018-03-30 06:03:28
Documents
9
Period of Report
2018-05-10
Effectiveness Date
2018-03-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A fprx-def14a_20180510.htm DEF 14A 3293687
2 GRAPHIC g2018032822354229634753.jpg GRAPHIC 2112
3 GRAPHIC g2018032822354697734756.jpg GRAPHIC 23429
4 GRAPHIC g2018032822355963934759.jpg GRAPHIC 47525
5 GRAPHIC g2018032822355956434757.jpg GRAPHIC 4134
6 GRAPHIC g2018032822355959434758.jpg GRAPHIC 49773
7 GRAPHIC g2018032822354354634755.jpg GRAPHIC 24933
8 GRAPHIC g2018032822354236534754.jpg GRAPHIC 4134
9 GRAPHIC g2018032822354221334752.jpg GRAPHIC 5963
  Complete submission text file 0001564590-18-007194.txt   3519145
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS INC (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36070 | Film No.: 18724792
SIC: 2834 Pharmaceutical Preparations